The advantages of using traditional Chinese medicine as an adjunctive therapy in the whole course of cancer treatment instead of only terminal stage of cancer

BioScience Trends

Volumn 9, Issue 1, 2015, Pages 16-34

  Qi, Fanghua ^a   Zhao, Lin ^a   Zhou, Aiyan ^a   Zhang, Bo ^b   Li, Anyuan ^a   Wang, Zhixue ^a   Han, Junqing ^a  

^a SHANDONG PROVINCIAL HOSPITAL AFFILIATED TO SHANDONG UNIVERSITY   (China)

^b SHANDONG PROVINCIAL HOSPITAL AFFILIATED TO SHANDONG FIRST MEDICAL UNIVERSITY   (China)

Author keywords

Adjunctive therapy; Chemotherapy; Post operation; Radiotherapy; The whole course of cancer treatment; Traditional Chinese medicine (TCM)

Indexed keywords

ENGELHARDIA ROXBURGHIANA; PANAX GINSENG;

HERBACEOUS AGENT;

ADJUVANT CHEMOTHERAPY; CHINESE MEDICINE; HUMAN; MULTIMODALITY CANCER THERAPY; NEOPLASMS; PROCEDURES; TERMINAL CARE;

CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; DRUGS, CHINESE HERBAL; HUMANS; MEDICINE, CHINESE TRADITIONAL; NEOPLASMS; TERMINAL CARE;

EID: 84924910955     PISSN: 18817815     EISSN: 18817823     Source Type: Journal    
DOI: 10.5582/bst.2015.01019     Document Type: Review

References (100)

1. WHO (2012). Non-Communicable Diseases. Burden: Mortality, Morbidity and Risk Factors. http://www.who. int/nmh/publications/ncd_report_chapter1.pdf (Accessed October, 24, 2014).
2. Hao J, Chen WQ. 2012 Chinese Cancer Registry Annual Report. National Cancer Center, Disease prevention and control bureau, Ministry of Health.
3. Targeted therapy. http://en.wikipedia.org/wiki/Targeted_therapy (Accessed October, 24, 2014).
4. Mellman I, Coukos G, Dranoff G. Cancer immunotherapy comes of age. Nature. 2011; 480:480-489.
5. Chen M, Guo Y. Consideration about the concept of "tumor-bearing survival". Zhong Hua Zhong Yi Yao Za Zhi. 2012; 27:3193-3194. (in Chinese)
6. Li X, Yang G, Li X, Zhang Y, Yang J, Chang J, Sun X, Zhou X, Guo Y, Xu Y, Liu J, Bensoussan A. Traditional Chinese medicine in cancer care: A review of controlled clinical studies published in Chinese. PLoS One. 2013; 8:e60338.
7. Zhou J, Zhou T, Jiang M, Wang X, Liu Q, Zhan Z, Zhang X. Research progress on synergistic anti-tumor mechanisms of compounds in traditional Chinese medicine. J Tradit Chin Med. 2014; 34:100-105.
8. Liang W, Yew DT, Hon KL, Wong CK, Kwok TC, Leung PC. Indispensable value of clinical trials in the modernization of traditional Chinese medicine: 12 years' experience at CUHK and future perspectives. Am J Chin Med. 2014; 42:587-604.
9. Ling CQ. My reviews on the etiology and pathogenesis of malignant cancer. Journal of Traditional Chinese Medicine. 2009; 50:952-953. (in Chinese)
10. Smith ME, Bauer-Wu S. Traditional Chinese Medicine for cancer-related symptoms. Semin Oncol Nurs. 2012; 28:64-74.
11. Chao TH, Fu PK, Chang CH, Chang SN, Chiahung Mao F, Lin CH; Evidence-based Chinese Medicine Research Group. Prescription patterns of Chinese herbal products for post-surgery colon cancer patients in Taiwan. J Ethnopharmacol. 2014; 155:702-708.
12. Qi F, Li A, Inagaki Y, Gao J, Li J, Kokudo N, Li XK, Tang W. Chinese herbal medicines as adjuvant treatment during chemo- or radio-therapy for cancer. Biosci Trends. 2010; 4:297-307.
13. Ling CQ, Yue XQ, Ling C. Three advantages of using traditional Chinese medicine to prevent and treat tumor. J Integr Med. 2014; 12:331-335.
14. Konkimalla VB, Efferth T. Evidence-based Chinese medicine for cancer therapy. J Ethnopharmacol. 2008; 116:207-210.
15. Xiang YZ, Shang HC, Gao XM, Zhang BL. A comparison of the ancient use of Ginseng in traditional Chinese medicine with modern pharmacological experiments and clinical trials. Phytother Res. 2008; 22:851-858.
16. Lee SY, Kim YK, Park N, Kim CS, Lee CY, Park SU. Chemical constituents and biological activities of the berry of Panax ginseng. J Med Plants Res. 2010; 5:349-353.
17. Sun YX. Structure and biological activities of the polysaccharides from the leaves, roots and fruits of Panax ginseng C.A. Meyer: An overview. Carbohydr Polym. 2011; 85:490-499.
18. Hofseth LJ, Wargovich MJ. Inflammation, cancer, and targets of ginseng. J Nutr. 2007; 137 (Suppl 1):183S-185S.
19. Yun TK. Experimental and epidemiological evidence on nonorgan specific cancer preventive effect of Korean ginseng and identification of active compounds. Mutat Res. 2003; 523-524:63-74.
20. Lee JH, Kwon KR, Cho CK, Han SS, Yoo HS. Advanced cancer cases treated with cultivated wild ginseng phamacopuncture. J Acupunct Meridian Stud. 2010; 3:119-124.
21. Barton DL, Liu H, Dakhil SR, Linquist B, Sloan JA, Nichols CR, McGinn TW, Stella PJ, Seeger GR, Sood A, Loprinzi CL. Wisconsin Ginseng (Panax quinquefolius) to improve cancer-related fatigue: A randomized, doubleblind trial, N07C2. J Natl Cancer Inst. 2013; 105:1230-1238.
22. Lee JM, Hah JO, Kim HS. The effect of red ginseng extract on inflammatory cytokines after chemotherapy in children. J Ginseng Res. 2012; 36:383-390.
23. Lee TK, Johnke RM, Allison RR, O'Brien KF, Dobbs LJ Jr. Radioprotective potential of ginseng. Mutagenesis. 2005; 20:237-243.
24. Qi LW, Cao J, Li P, Yu QT, Wen XD, Wang YX, Li CY, Bao KD, Ge XX, Cheng XL. Qualitative and quantitative analysis of Radix Astragali products by fast highperformance liquid chromatography-diode array detection coupled with time-of-flight mass spectrometry through dynamic adjustment of fragmentor voltage. J Chromatogr A. 2008; 1203:27-35.
25. Yan MM, Liu W, Fu YJ, Zu YG, Chen CY, Luo M. Optimisation of the microwave-assisted extraction process for four main astragalosides in Radix Astragali. Food Chem. 119:1663-1670.
26. Li J, Bao Y, Lam W, Li W, Lu F, Zhu X, Liu J, Wang H. Immunoregulatory and anti-tumor effects of polysaccharopeptide and Astragalus polysaccharides on tumor-bearing mice. Immunopharmacol Immunotoxicol. 2008; 30:771-782.
27. Law PC, Auyeung KK, Chan LY, Ko JK. Astragalus saponins downregulate vascular endothelial growth factor under cobalt chloride-stimulated hypoxia in colon cancer cells. BMC Complement Altern Med. 2012; 12:160.
28. Lin YW, Chiang BH. Anti-tumor activity of the fermentation broth of Cordyceps militaris cultured in the medium of Radix astragali. Process Biochem. 2008; 43:244-250.
29. Taixiang W, Munro AJ, Guanjian L. Chinese medical herbs for chemotherapy side effects in colorectal cancer patients. Cochrane Database Syst Rev. 2005; 1:CD004540.
30. Yan PH, Yan M, Wang XM, Wang SH. Effect of Huangqi injection on short-term prognosis in children with acute lymphoblastic leukemia. Zhongguo Dang Dai Er Ke Za Zhi. 2014; 16:141-146. (in Chinese)
31. Li Y, Cui HJ, Huang JC, Wu XQ. Clinical study of Jiawei Huangqi Guizhi Wuwu Decoction in preventing and treating peripheral neuro-sensory toxicity caused by oxaliplatin. Chin J Integr Med. 2006; 12:19-23.
32. The State Pharmacopoeia Commission of the People's Republic of China. Pharmacopoeia of the People's Republic of China 2010. China Chemical Industry Press, Beijing, China, 2010.
33. Yang C, Gou Y, Chen J, An J, Chen W, Hu F. Structural characterization and antitumor activity of a pectic polysaccharide from Codonopsis pilosula. Carbohydr Polym. 2013; 98:886-895.
34. Xin T, Zhang F, Jiang Q, Chen C, Huang D, Li Y, Shen W, Jin Y, Sui G. The inhibitory effect of a polysaccharide from Codonopsis pilosula on tumor growth and metastasis in vitro. Int J Biol Macromol. 2012; 51:788-793.
35. Sun Y. Biological activities and potential health benefits of polysaccharides from Poria cocos and their derivatives. Int J Biol Macromol. 2014; 68:131-134.
36. Ríos JL. Chemical constituents and pharmacological properties of Poria cocos. Planta Med. 2011; 77:681-691.
37. Cheng S, Eliaz I, Lin J, Thyagarajan-Sahu A, Sliva D. Triterpenes from Poria cocos suppress growth and invasiveness of pancreatic cancer cells through the downregulation of MMP-7. Int J Oncol. 2013; 42:1869-1874.
38. Kikuchi T, Uchiyama E, Ukiya M, Tabata K, Kimura Y, Suzuki T, Akihisa T. Cytotoxic and apoptosis-inducing activities of triterpene acids from Poria cocos. J Nat Prod. 2011; 74:137-144.
39. Chen M, May BH, Zhou IW, Xue CC, Zhang AL. FOLFOX 4 combined with herbal medicine for advanced colorectal cancer: A systematic review. Phytother Res. 2014; 28:976-991.
40. Niu Y, Meng QX. Chemical and preclinical studies on Hedyotis diffusa with anticancer potential. J Asian Nat Prod Res. 2013; 15:550-565.
41. Kuo YJ, Yang JS, Lu CC, Chiang SY, Lin JG, Chung JG. Ethanol extract of Hedyotis diffusa willd upregulates G0/G1 phase arrest and induces apoptosis in human leukemia cells by modulating caspase cascade signaling and altering associated genes expression was assayed by cDNA microarray. Environ Toxicol. 2014; doi:10.1002/tox.21989.
42. Cai Q, Lin J, Wei L, Zhang L, Wang L, Zhan Y, Zeng J, Xu W, Shen A, Hong Z, Peng J. Hedyotis diffusa Willd inhibits colorectal cancer growth in vivo via inhibition of STAT3 signaling pathway. Int J Mol Sci. 2012; 13:6117-6128.
43. Lee SZ, Huang TC, Wei MC, Yang YC. Extraction of protocatechuic acid from Scutellaria barbata D. Don using supercritical carbon dioxide. J Supercrit Fluid. 2013; 81:55-66.
44. Nie XP, Qu GW, Yue XD, Li GS, Dai SJ. Scutelinquanines A-C, three new cytotoxic neo-clerodane diterpenoid from Scutellaria barbata. Phytochem Lett. 2010; 3:190-193.
45. Lin J, Chen Y, Cai Q, Wei L, Zhan Y, Shen A, Sferra TJ, Peng J. Scutellaria Barbata D Don Inhibits Colorectal Cancer Growth via Suppression of Multiple Signaling Pathways. Integr Cancer Ther. 2013; 13:240-248.
46. Perez AT, Arun B, Tripathy D, Tagliaferri MA, Shaw HS, Kimmick GG, Cohen I, Shtivelman E, Caygill KA, Grady D, Schactman M, Shapiro CL. A phase 1B dose escalation trial of Scutellaria barbata (BZL101) for patients with metastatic breast cancer. Breast Cancer Res Treat. 2010; 120:111-118.
47. Chen XP, Li W, Xiao XF, Zhang LL, Liu CX. Phytochemical and pharmacological studies on Radix Angelica sinensis. Chin J Nat Med. 2013; 11:577-587.
48. Chao WW, Lin BF. Bioactivities of major constituents isolated from Angelica sinensis (Danggui). Chinese Medicine. 2011; 6:29.
49. Kou W, Li YD, Liu K, Sun SB, Dong YM, Wu ZH. Radix Angelicae Sinensis and Radix Hedysari enhance radiosensitivity of 12C6+ radiation in human liver cancer cells by modulating apoptosis protein. Saudi Med J. 2014; 35:945-952.
50. Kumar P, Kadakol A, Shasthrula P, Mundhe NA, Jamdade VS, Barua CC, Gaikwad AB. Curcumin as an Adjuvant to Breast Cancer Treatment. Anticancer Agents Med Chem. 2015. [Epub ahead of print]
51. Goel A, Aggarwal BB. Curcumin, the golden spice from Indian saffron, is a chemosensitizer and radiosensitizer for tumors and chemoprotector and radioprotector for normal organs. Nutr Cancer. 2010; 62:919-930.
52. Qi FH, Wang ZX, Cai PP, Zhao L, Gao JJ, Kokudo N, Li AY, Han JQ, Tang W. Traditional Chinese medicine and related active compounds: A review of their role on hepatitis B virus infection. Drug Discov Ther. 2013; 7:212-224.
53. Kido T, Mori K, Daikuhara H, Tsuchiya H, Ishige A, Sasaki H. The protective effect of hochu-ekki-to (TJ-41), a Japanese herbal medicine, against HSV-1 infection in mitomycin C-treated mice. Anticancer Res. 2000; 20:4109-4113.
54. Kimura M, Sasada T, Kanai M, Kawai Y, Yoshida Y, Hayashi E, Iwata S, Takabayashi A. Preventive effect of a traditional herbal medicine, Hochu-ekki-to, on immunosuppression induced by surgical stress. Surg Today. 2008; 38:316-322.
55. Jeong JS, Ryu BH, Kim JS, Park JW, Choi WC, Yoon SW. Bojungikki-tang for cancer-related fatigue: A pilot randomized clinical trial. Integr Cancer Ther. 2010; 9:331-338.
56. Ogawa K, Omatsu T, Matsumoto C, Tsuchiya N, Yamamoto M, Naito Y, Yoshikawa T. Protective effect of the Japanese traditional medicine juzentaihoto on myelosuppression induced by the anticancer drug TS-1 and identification of a potential biomarker of this effect. BMC Complement Altern Med. 2012; 12:118.
57. Huang SM, Chien LY, Tai CJ, Chiou JF, Chen CS, Tai CJ. Effectiveness of 3-week intervention of Shi Quan Da Bu Tang for alleviating hematotoxicity among patients with breast carcinoma receiving chemotherapy. Integr Cancer Ther. 2013; 12:136-144.
58. Tsuchiya M, Kono H, Matsuda M, Fujii H, Rusyn I. Protective effect of Juzen-taiho-to on hepatocarcinogenesis is mediated through the inhibition of Kupffer cell-induced oxidative stress. Int J Cancer. 2008; 123:2503-2511.
59. Ikemoto T, Shimada M, Iwahashi S, Saito Y, Kanamoto M, Mori H, Morine Y, Imura S, Utsunomiya T. Changes of immunological parameters with administration of Japanese Kampo medicine (Juzen-Taihoto/TJ-48) in patients with advanced pancreatic cancer. Int J Clin Oncol. 2014; 19:81-86.
60. Liu SH, Cheng YC. Old formula, new Rx: The journey of PHY906 as cancer adjuvant therapy. J Ethnopharmacol. 2012; 140:614-623.
61. Rockwell S, Grove TA, Liu Y, Cheng YC, Higgins SA, Booth CJ. Preclinical studies of the Chinese herbal medicine formulation PHY906 (KD018) as a potential adjunct to radiation therapy. Int J Radiat Biol. 2013; 89:16-25.
62. Saif MW, Li J, Lamb L, Kaley K, Elligers K, Jiang Z, Bussom S, Liu SH, Cheng YC. First-in-human phase II trial of the botanical formulation PHY906 with capecitabine as second-line therapy in patients with advanced pancreatic cancer. Cancer Chemother Pharmacol. 2014; 73:373-380.
63. Qi FH, Wang ZX, Cai PP, Zhao L, Gao JJ, Kokudo N, Li AY, Han JQ, Tang W. Traditional Chinese medicine and related active compounds: A review of their role on hepatitis B virus infection. Drug Discov Ther. 2013; 7:212-224.
64. Zheng CS, Wu YS, Bao HJ, Xu XJ, Chen XQ, Ye HZ, Wu GW, Xu HF, Li XH, Chen JS, Liu XX. Understanding the polypharmacological anticancer effects of Xiao Chai Hu Tang via a computational pharmacological model. Exp Ther Med. 2014; 7:1777-1783.
65. Li J, Xie M, Gan Y. Effect of Xiaochaihu decoction and different herbal formulation of component on inhibiting H22 liver cancer in mice and enhancing immune function. Zhongguo Zhong Yao Za Zhi. 2008; 33:1039-1044. (in Chinese)
66. Rino Y, Tarao K, Morinaga S, Ohkawa S, Miyakawa K, Hirokawa S, Masaki T, Tarao N, Yukawa N, Saeki H, Takanashi Y, Imada T. Reduction therapy of alanine aminotransferase levels prevent HCC development in patients with HCV-associated cirrhosis. Anticancer Res. 2006; 26:2221-2226.
67. Matsuoka H, Mizushima Y, Kawano M, Tachibana N, Sawada Y, Kato S, Nagakura H, Tanaka M, Suzuki K, Tadanobu K. Clinical availability of the herbal medicine, SYOUSAIKOTOU, as a gargling agent for prevention and treatment of chemotherapy-induced stomatitis. Gan To Kagaku Ryoho. 2004; 31:2017-2020. (in Japanese)
68. Wang S, Wu X, Tan M, Gong J, Tan W, Bian B, Chen M, Wang Y. Fighting fire with fire: Poisonous Chinese herbal medicine for cancer therapy. J Ethnopharmacol. 2012; 140:33-45.
69. Li J, Wang JC, Ma B, Gao W, Chen P, Sun R, Yang KH. Shenqi Fuzheng Injection (SFI) for advanced gastric cancer: A systematic review of randomized controlled trials. Chin J Integr Med. 2015; 21:71-79.
70. Dong J, Su SY, Wang MY, Zhan Z. Shenqi fuzheng, an injection concocted from Chinese medicinal herbs, combined with platinum-based chemotherapy for advanced non-small cell lung cancer: A systematic review. J Exp Clin Cancer Res. 2010; 29:137.
71. Guo ML, Chen HY, Han XL, Zhang HZ. Influence of Shenqi fuzheng injection combined with radiochemotherapy on quality of life in head and neck cancer patients. Modern Journal of Integrated Traditional Chinese and Western Medicine. 2014; 23:1273-1275. (in Chinese)
72. Liu X, Yang Q, Xi Y, Yu K, Wang W, Zhao X, Kou X. Kanglaite injection combined with chemotherapy versus chemotherapy alone in the treatment of advanced nonsmall cell lung carcinoma. J Cancer Res Ther. 2014; 10 (Suppl 1):46-51.
73. Fu F, Wan Y, Mulati, Wu T. Kanglaite injection combined with hepatic arterial intervention for unresectable hepatocellular carcinoma: A meta-analysis. J Cancer Res Ther. 2014; 10 (Suppl 1):38-41.
74. Wang JC, Tian JH, Ge L, Gan YH, Yang KH. Which is the best Chinese herb injection based on the FOLFOX regimen for gastric cancer? A network meta-analysis of randomized controlled trials. Asian Pac J Cancer Prev. 2014; 15:4795-4800.
75. Qi F, Li A, Inagaki Y, Kokudo N, Tamura S, Nakata M, Tang W. Antitumor activity of extracts and compounds from the skin of the toad Bufo bufo gargarizans Cantor. Int Immunopharmacol. 2011; 11:342-349.
76. Qi F, Li A, Inagaki Y, Xu H, Wang D, Cui X, Zhang L, Kokudo N, Du G, Tang W. Induction of apoptosis by cinobufacini preparation through mitochondria- and Fas-mediated caspase-dependent pathway. Food Chem Toxicol. 2012; 50:295-302.
77. Meng Z, Yang P, Shen Y, Bei W, Zhang Y, Ge Y, Newman RA, Cohen L, Liu L, Thornton B, Chang DZ, Liao Z, Kurzrock R. Pilot study of huachansu in patients with hepatocellular carcinoma, nonsmall-cell lung cancer, or pancreatic cancer. Cancer. 2009; 115:5309-5318.
78. Qin TJ, Zhao XH, Yun J, Zhang LX, Ruan ZP, Pan BR. Efficacy and safety of gemcitabine-oxaliplatin combined with huachansu in patients with advanced gallbladder carcinoma. World J Gastroenterol. 2008; 14:5210-5216.
79. Chen Z, Chen HY, Lang QB, Li B, Zhai XF, Guo YY, Yue XQ, Ling CQ. Preventive effects of jiedu granules combined with cinobufacini injection versus transcatheter arterial chemoembolization in post-surgical patients with hepatocellular carcinoma: A case-control trial. Chin J Integr Med. 2012; 18:339-344.
80. Sun T, Zhang Y, Shen Y, Hu K, Zuo M. A case of advanced lung cancer with malignant pericardial effusion treated by intrapericardial Cinobufacini injection instillation. Biosci Trends. 2014; 8:235-239.
81. Wang MJ, Nan X, Feng G, Yu HT, Hu GF, Liu YQ. Design, synthesis and bioactivity evaluation of novel acylthiourea derivatives of cantharidin. Ind Crop Prod. 2014; 55:11-18.
82. Han L, Sun YJ, Pan YF, Ding H, Chen X, Zhang X. Cantharidin combined with chemotherapy for Chinese patients with metastatic colorectal cancer. Asian Pac J Cancer Prev. 2014; 15:10977-10979.
83. Ji ZQ, Huang XE, Wu XY, Liu J, Wang L, Tang JH. Safety of Brucea javanica and cantharidin combined with chemotherapy for treatment of NSCLC patients. Asian Pac J Cancer Prev. 2014; 15:8603-8605.
84. Patricolo GE, Armstrong K, Riutta J, Lanni T. Lymphedema care for the breast cancer patient: An integrative approach. Breast. 2015; 24:82-85.
85. Wanchai A, Armer JM, Stewart BR. Complementary and alternative medicine and lymphedema. Semin Oncol Nurs. 2013; 29:41-49.
86. Casley-Smith JR, Morgan RG, Piller NB. Treatment of lymphedema of the arms and legs with 5,6-benzo-[alpha]-pyrone. N Engl J Med. 1993; 329:1158-1163.
87. Loprinzi CL, Kugler JW, Sloan JA, Rooke TW, Quella SK, Novotny P, Mowat RB, Michalak JC, Stella PJ, Levitt R, Tschetter LK, Windschitl H. Lack of effect of coumarin in women with lymphedema after treatment for breast cancer. N Engl J Med. 1999; 340:346-350.
88. Jiang ZM. Upper extremity lymphedema treated with compound Diosmin and Sodium aescine after breast cancer surgery. World Journal of Integrated Traditional and Western Medicine. 2010; 5:341-342. (in Chinese)
89. Takeda H, Muto S, Nakagawa K, Ohnishi S, Sadakane C, Saegusa Y, Nahata M, Hattori T, Asaka M. Rikkunshito as a ghrelin enhancer. Methods Enzymol. 2012; 514:333-351.
90. Gunji S, Ueda S, Yoshida M, Kanai M, Terajima H, Takabayashi A. Effects of rikkunshito, a kampo medicine, on quality of life after proximal gastrectomy. J Surg Res. 2013; 185:575-580.
91. Chen HY, Li SG, Cho WC, Zhang ZJ. The role of acupoint stimulation as an adjunct therapy for lung cancer: A systematic review and meta-analysis. BMC Complement Altern Med. 2013; 13:362.
92. Wang SJ, Xu J, Gong DD, Man CF, Fan Y. Meta-analysis of oral Chinese herbal medicine as an adjuvant treatment in relieving pain secondary to bone metastases. Chin J Integr Med. 2013 Oct 14. [Epub ahead of print]
93. Yanju B, Yang L, Hua B, Hou W, Shi Z, Li W, Li C, Chen C, Liu R, Qin Y, Lv W. A systematic review and meta-analysis on the use of traditional Chinese medicine compound kushen injection for bone cancer pain. Support Care Cancer. 2014; 22:825-836.
94. Su CX, Wang LQ, Grant SJ, Liu JP. Chinese herbal medicine for cancer-related fatigue: A systematic review of randomized clinical trials. Complement Ther Med. 2014; 22:567-579.
95. Lo LC, Chen CY, Chen ST, Chen HC, Lee TC, Chang CS. Therapeutic efficacy of traditional Chinese medicine, Shen-Mai San, in cancer patients undergoing chemotherapy or radiotherapy: Study protocol for a randomized, double-blind, placebo-controlled trial. Trials. 2012; 13:232.
96. Fu L, Fu H, Liu LQ, Huo ZJ, Yu YH, Yu JM. Efficacy of donkey-hide gelatin mixture for gemcitabine and cisplatin chemotherapy regimen induced myelosuppression. Chinese Clinical Oncology. 2014; 19:739-742. (in Chinese)
97. Zhang PY, Qiu N. The clinical observation on Shiquan-da-bu-tang relieving myelosuppression caused by chemotherapy. Modern Journal of Integrated Traditional Chinese and Western Medicine. 2009; 18:2157-2158. (in Chinese)
98. Zheng W, Gao ZH, Wu LN. Clinical observation on treatment of radiative pneumonia in patients with lung cancer by integrative Chinese and Western medicine. Zhongguo Zhong Xi Yi Jie He Za Zhi. 2007; 27:1121-1123. (in Chinese)
99. Xiao C, Ding HJ, Feng LC, Qu BL, Dou YQ. Efficacy of Liangxue Jiedu Huoxue Decoction in prevention of radiation pneumonitis: A randomized controlled trial. Zhong Xi Yi Jie He Xue Bao. 2010; 8:624-628. (in Chinese)
100. Liu ML, Chien LY, Tai CJ, Lin KC, Tai CJ. Effectiveness of Traditional Chinese Medicine for Liver Protection and Chemotherapy Completion among Cancer Patients. Evid Based Complement Alternat Med. 2011; 2011:291843. (Received January 10, 2015; Revised February 20, 2015; Accepted February 23, 2015)